Literature DB >> 21952277

Vaccines for colorectal cancer and renal cell carcinoma.

Katherine Kabaker1, Kathryn Shell, Howard L Kaufman.   

Abstract

Vaccines have shown promise for the prevention and treatment of solid tumors. Colorectal cancer and renal cell carcinoma are common malignancies that may be amenable to vaccine strategies. This review summarizes target antigens in colorectal and renal cell carcinoma, discusses some of the vaccine approaches in development, and details the results of pivotal phase III trials evaluating therapeutic vaccines in patients with advanced colorectal and renal cell carcinoma. Finally, some of the challenges with vaccine development for colorectal and renal cell carcinoma are described.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21952277     DOI： 10.1097/PPO.0b013e318232ff44

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  4 in total

1.  Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.

Authors:  J Bae; T Hideshima; G L Zhang; J Zhou; D B Keskin; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

2.  Potential association factors for developing effective peptide-based cancer vaccines.

Authors:  Chongming Jiang; Jianrong Li; Wei Zhang; Zhenkun Zhuang; Geng Liu; Wei Hong; Bo Li; Xiuqing Zhang; Cheng-Chi Chao
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

3.  Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.

Authors:  Hiroyuki Suzuki; Mitsuro Fukuhara; Takumi Yamaura; Satoshi Mutoh; Naoyuki Okabe; Hiroshi Yaginuma; Takeo Hasegawa; Atsushi Yonechi; Jun Osugi; Mika Hoshino; Takashi Kimura; Mitsunori Higuchi; Yutaka Shio; Kazuya Ise; Kazuyoshi Takeda; Mitsukazu Gotoh
Journal:  J Transl Med       Date:  2013-04-11       Impact factor: 5.531

4.  A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.

Authors:  J Bae; R Prabhala; A Voskertchian; A Brown; C Maguire; P Richardson; G Dranoff; K C Anderson; N C Munshi
Journal:  Leukemia       Date:  2014-05-14       Impact factor: 11.528
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.